A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study
Year: 2004
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: Docetaxel (75 mg m(-2) 3-weekly) is standard second-line treatment in advanced non-small-cell lung cancer (NSCLC) with significant toxicity. To verify whether a weekly schedule (33.3 mg m(-2) for 6 weeks) improved quality of life (QoL), a phase III study was performed with 220 advanced NSCLC patients, < or =75 years, ECOG PS < or =2. QoL was assessed by EORTC questionnaires and the Daily Diary Card (DDC). No difference was found in global QoL scores at 3 weeks. Pain, cough and hair loss significantly favoured the weekly schedule, while diarrhoea was worse. DDC analysis showed that loss of appetite and overall condition were significantly worse in the 3-week arm in the first week, while nausea and loss of appetite were more severe in the weekly arm in the third week. Response rate and survival were similar, hazard ratio of death in the weekly arm being 1.04 (95% CI 0.77-1.39). A 3-weekly docetaxel was more toxic for leukopenia, neutropenia, febrile neutropenia and hair loss; any grade 3-4 haematologic toxicity was significantly more frequent in the standard arm (25 vs 6%). The weekly schedule could be preferred for patients candidate to receive docetaxel as second-line treatment for advanced NSCLC, because of some QoL advantages, lower toxicity and no evidence of strikingly different effect on survival.
Source: British Journal of Cancer
Authors: on behalf of the DISTAL (Docetaxel In Second-line Treatment of Advanced Lung cancer) Investigators, C Gridelli, C Gallo, M Di Maio, E Barletta, A Illiano, P Maione, S Salvagni, F V Piantedosi, G Palazzolo, O Caffo, A Ceribelli, A Falcone, P Mazzanti, L Brancaccio, M A Capuano, L Isa, S Barbera, F Perrone
Institutions: Azienda Ospedaliera S.Giuseppe Moscati, University of Campania "Luigi Vanvitelli", Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Ospedale Monaldi, Ospedale di Parma, Ospedale Santa Chiara, Instituto Nazionale Tumori Regina Elena, Ospedale di Livorno, Azienda Ospedaliero-Universitaria delle Marche, Ospedali Riuniti di Foggia, Azienda Ospedaliera di Cosenza
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,190
OpenAlex ID: W2053432470
